| Authors: |
Abrisqueta P; Hospital Universitario Vall d'Hebron, Barcelona, Spain. pabrisqueta@vhio.net., Karimi YH; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Morillo D; Fundacion Jimenez Diaz University Hospital, Start Madrid - FJD Early Phase Unit, Health Research Institute IIS-FJD, Madrid, Spain., Cordoba R; Fundacion Jimenez Diaz University Hospital, Start Madrid - FJD Early Phase Unit, Health Research Institute IIS-FJD, Madrid, Spain., Phillips T; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., De Vos S; Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA., Nijland M; University Medical Center Groningen and University of Groningen, Groningen, the Netherlands., Offner F; Universitair Ziekenhuis Gent, Ghent, Belgium., Andersson PO; Gothenburg University, Sahlgrenska Academy, Gothenburg, Sweden., Brody J; Icahn School of Medicine at Mount Sinai, New York, NY., Cheah CY; Sir Charles Gairdner Hospital and the University of Western Australia, Perth, WA, Australia., Prieto PG; Hospital Universitairo La Paz, Madrid, Spain., Hellström M; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Jørgensen JM; Aarhus University Hospital, Aarhus, Denmark., Lewis D; University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom., Linton KM; Christie NHS Foundation Trust, Manchester Cancer Research Centre and Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom., Musuraca G; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola., Wang L; Genmab, Princeton, NJ., Marek J; Genmab, Princeton, NJ., Osei-Bonsu K; AbbVie, North Chicago, IL., Risum M; Genmab, Copenhagen, Denmark., Falchi L; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY. |
